aTyr Pharma (NASDAQ:LIFE) reported Q4 EPS of ($0.26), $0.22 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $10.4 thousand versus the consensus estimate of $416.67 thousand.
aTyr Pharma (NASDAQ:LIFE) reported Q4 EPS of ($0.26), $0.22 better than the analyst estimate of ($0.48). Revenue for the quarter came in at $10.4 thousand versus the consensus estimate of $416.67 thousand.